ArticleMicrobial cell factories2025
Metabolic engineering of Saccharomyces cerevisiae for neoxanthin production.
Article in Microbial cell factories, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundXanthophylls, a subclass of oxygenated carotenoids, are highly valued for their wide range of applications in the food and pharmaceutical industries, particularly due to their antioxidant properties and potential health benefits. Among these, neoxanthin, a less studied xanthophyll, has demonstrated significant therapeutic potential, including antioxidant and anticancer activities. Neoxanthin is also the primary precursor for the synthesis of other valuable compounds, such as fucoxanthin and β-damascenone, which are important in the cosmetic and pharmaceutical sectors.
resultsIn this study, we report the first heterologous production of neoxanthin in Saccharomyces cerevisiae through a combination of metabolic and enzyme engineering. First, a S. cerevisiae strain was engineered to produce neoxanthin by expressing genes from the β-carotene and violaxanthin biosynthesis pathways. Following this, the VDL1 gene from Phaeodactylum tricornutum, responsible for converting violaxanthin into neoxanthin, was expressed, resulting in the production of 0.18 mg/g
conclusionsThis is the highest reported yield of neoxanthin produced by engineered microorganisms, and the strategies employed here have considerable potential for scaling up production of this carotenoid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.